Arbovirus Testing Market Size Valued at USD 1.25 Billion in 2024, Driven by Global Surveillance Initiatives

The arbovirus testing market size was valued at USD 1.25 billion in 2024 and is expected to reach USD 1.78 billion by 2032, growing at a CAGR of 4.59% over the forecast period of 2025–2032. This growth is primarily supported by increasing incidences of dengue, Zika, chikungunya, and other arboviral infections worldwide. Expanding mosquito habitats due to climate change, rapid urbanization, and global travel have intensified disease transmission, compelling healthcare systems to strengthen diagnostic preparedness and surveillance infrastructure.

Strong government initiatives remain a core driver for market expansion. Public health authorities across developed and developing economies are prioritizing early detection, outbreak monitoring, and laboratory modernization. Regulatory frameworks ensuring diagnostic accuracy, along with funding support for research institutions and diagnostic manufacturers, are accelerating innovation. Global collaborations, including WHO-led programs, are promoting harmonized surveillance and faster adoption of advanced diagnostic technologies, reinforcing sustained demand across healthcare ecosystems.

Get free Sample Report@ https://www.snsinsider.com/sample-request/8001

In October 2024, the U.S. Centers for Disease Control and Prevention increased arbovirus surveillance funding by USD 90 million to expand RT-PCR testing capacity in high-risk states such as Florida, Texas, and California. Such initiatives highlight the importance of molecular diagnostics in managing outbreaks and improving public health outcomes. The growing emphasis on awareness campaigns and laboratory training programs further supports widespread test adoption globally.

The U.S. arbovirus testing market was valued at USD 320.84 million in 2024 and is projected to reach USD 453.03 million by 2032, registering a CAGR of 4.44%. The country leads the market due to the rapid integration of telemedicine, which facilitates early symptom assessment, remote consultations, and timely test ordering. Federal reimbursement support and flexible telehealth regulations have enhanced access to RT-PCR and serological testing, particularly in underserved regions. In 2024, telemedicine-based arbovirus consultations in the U.S. increased by 48%, surpassing 1.2 million cases, driven by Medicare-backed and CDC-supported programs.

Rising global incidence of dengue and Zika is a major growth driver. The absence of specific antiviral therapies and the high socioeconomic burden associated with outbreaks have pushed governments to invest heavily in diagnostic infrastructure. In May 2025, WHO reported 6.8 million dengue cases globally in early 2025, reflecting a 24% rise from 2024, which significantly increased demand for reliable arbovirus testing solutions.

However, supply chain disruptions and limited diagnostic access restrain market growth in low-resource regions. Poor laboratory infrastructure, high costs, and reliance on centralized facilities restrict timely testing. In January 2025, PAHO reported over 40% underreporting of arboviral cases in parts of Central America and the Caribbean due to inadequate lab access and trained personnel, limiting broader market penetration.

By type, ELISA-based tests dominated the market with a 46.86% share in 2024, supported by cost-effectiveness and suitability for mass screening. RT-PCR-based tests are the fastest-growing segment, expanding at a CAGR of 5.05%, driven by high sensitivity, early infection detection, and expanding laboratory infrastructure. By end user, diagnostic laboratories led the market due to large-scale testing capabilities, while research centers are growing rapidly with increased R&D investment in next-generation diagnostics.

Regionally, North America accounted for 40.60% of revenue in 2024 due to strong surveillance systems and public awareness. Asia Pacific is projected to grow at the fastest CAGR of 5.47%, supported by high disease burden, government investments, and expanding point-of-care testing.

Buy Full Report Now: https://www.snsinsider.com/checkout/8001

FAQ

Q1. What is driving the growth of the arbovirus testing market?

Rising dengue and Zika cases, government surveillance initiatives, and diagnostic advancements are key drivers.

Q2. Which test type dominates the market?

ELISA-based tests dominate due to affordability and scalability.

Q3. Which region leads the market?

North America leads due to advanced healthcare infrastructure and awareness.

Q4. What is the fastest-growing segment?

RT-PCR-based testing is the fastest-growing segment.

Q5. What challenges affect market expansion?

Limited lab access, supply chain issues, and underreporting in low-resource regions remain key challenges.

Other Trending Reports

Injection Pen Market

3D Printing Medical Devices Market

Biotechnology Market

Lymphoma Treatment Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Rohan Jadhav - Principal Consultant

Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Email: info@snsinsider.com